MOSARĀ®

Forms and presentation
Coated tablets: Box of 20.
 
Composition
Each tablet contains: Mosapride citrate: 5 mg.
 
Indications
For the treatment of:
-Non-ulcer dyspepsia.
-Gastrointestinal symptoms (heartburns, nause, vomiting)
-Maintenance treatment of reflux esophagitis.
-Symptoms and lesions associated with gastroesophageal reflux.
 
Contraindications
Mosapride is contraindicated in patients with:
-Prior hypersensitivity to mosapride.
-Gastrointestinal perforation, obstruction, or hemorrhage.
 
Precautions
Renal impairment
Pharmacokinetic data in patients with renal impariment is unavailable. There is a potential for reduced clearance of metabolites.
 
Drug interactions
Agents that may rapidly induce hypokalemia.
 
 
Pregnancy 
Mosapride should only be taaken during pregnancy if the benefits justify the potential risks. The safety and efficacy of mosapride during human pregnancy have not been established.
 
Lactation
The degree to which mosapride is excreted into human milk is unknown. Women should therefore be advised to avoid breatfeeding while taking mosapride.
 
 
Dosage and administration
Administer 15mg of mosapride citrate per day (3 tablets 5 mg), split into 3 doses before or after meals.
Renal or hepatic impairment: The initial dose should not exceed 2.5mg, 3 times a day.
 
Overdosage
Consult your doctor, pharmacist or go to the hospital and take your medicines with you.
 
 
 
Origin: Argentine
Laboratories: Phoenix S.A.I.C.Y.F.
Distributor: Droguerie Phenicia
Number of Registration : 194340/05
 

Back